Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 13/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348816 | 0.86 | MGLL (0.53) | MGLLHTR1AADRA1ADDAH1HSP90AA1 | |
| SCHEMBL7633213 | 0.81 | MGLL (0.63) | MGLLDDAH1HSP90AA1NPSR1TDP1 | |
| SCHEMBL1574429 | 0.80 | AKR1C3 (0.58) | HTR1AADRA1AALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL31207305 | 0.80 | HTR1A (0.64) | HTR1AADRA1AALDH1A1HPGD | |
| SCHEMBL27264219 | 0.80 | HTR1A (0.64) | HTR1AADRA1AALDH1A1HPGD | |
| SCHEMBL6788274 | 0.78 | MGLL (0.65) | MGLLDDAH1HSP90AA1NPSR1TDP1 | |
| SCHEMBL10780780 | 0.77 | MGLL (0.65) | MGLLADRA1ADDAH1HSP90AA1NPSR1 | |
| SCHEMBL28308627 | 0.77 | MGLL (0.59) | MGLLDDAH1HSP90AA1NPSR1TDP1 | |
| SCHEMBL2125273 | 0.77 | ALDH1A1 (0.46) | MGLLHTR1AADRA1ADDAH1HSP90AA1 | |
| SCHEMBL19134296 | 0.76 | MGLL (0.67) | MGLLHSP90AA1NPSR1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712423-B2 | Methods and compositions for modifying mucous membranes | ABBOTT NICHOLAS L (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2013130684-A1 | XTEN-FOLATE CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX OPERATING INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2262474-A2 | METHODS AND COMPOSITIONS FOR WOUND HEALING | Mcanulty, Jonathan (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009097508-A2 | METHODS AND COMPOSITIONS FOR WOUND HEALING | MCANULTY, JONATHAN (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20080119421-A1 | Process for treating a biological organism | TECHNOLOGY INNOVATIONS, LLC | 2008-05-22 | — | — | US | disclosed |
| US-20050249667-A1 | Process for treating a biological organism | TECHNOLOGY INNOVATIONS, LLC | 2005-11-10 | — | — | US | disclosed |
| EP-0983095-B1 | PEPTIDE-COATED IMPLANTS AND METHODS FOR PRODUCING THEM | BIOMET DEUTSCHLAND GMBH (DE) | 2004-09-29 | — | — | EP | disclosed |
| EP-0983095-A2 | PEPTIDE-COATED IMPLANTS AND METHODS FOR PRODUCING SAME | MERCK PATENT GmbH (DE) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999059643-A2 | LIPOSOMAL DELIVERY COMPLEX | SDG, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1998052619-A2 | PEPTIDE-COATED IMPLANTS AND METHODS FOR PRODUCING SAME | MERCK PATENT GMBH (DE) | 1998-11-26 | — | — | WO | disclosed |
| US-5411730-A | Iron oxide and dextran, delivering to tumor and heating with radio frequency | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5399331-A | Drug delivery, medical diagnosis | THE LIPOSOME COMPANY, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0414741-B1 | FURTHER IMPROVEMENTS RELATING TO DRUG DELIVERY SYSTEMS | CANCER RES CAMPAIGN TECH (GB) | 1995-03-15 | — | — | EP | disclosed |
| EP-0641388-A1 | ION-CAPTURE ASSAYS USING A BINDING MEMBER CONJUGATED TO CARBOXYMETHYLAMYLOSE | ABBOTT LABORATORIES (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0586605-A1 | REAGENTS AND METHODS FOR PERFORMING TWO-STEP ION-CAPTURE BINDING ASSAYS | ABBOTT LABORATORIES (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992021772-A1 | ION-CAPTURE ASSAYS USING A BINDING MEMBER CONJUGATED TO CARBOXYMETHYLAMYLOSE | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1992021770-A1 | REAGENTS AND METHODS FOR PERFORMING TWO-STEP ION-CAPTURE BINDING ASSAYS | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1991000289-A2 | TARGETED LIPOSOMES AND METHODS FOR LIPOSOME-PROTEIN COUPLING | THE LIPOSOME COMPANY, INC. (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0398305-A2 | Anthracycline conjugates having a novel linker and methods for their production | Bristol-Myers Squibb Company (US) | 1990-11-22 | — | — | EP | disclosed |
| EP-0328147-A2 | Anthracycline immunoconjugates having a novel linker and methods for their production | Bristol-Myers Squibb Company (US) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119421-A1 | Process for treating a biological organism | BUB1, BOD1L1, BUB1B | MGLL 4491/4885HTR1A 4271/4885ADRA1A 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.